Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Price Target at $12.33
by Tristan Rich · The Markets DailyDiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $12.3333.
A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th.
Get Our Latest Stock Analysis on DiaMedica Therapeutics
Hedge Funds Weigh In On DiaMedica Therapeutics
Large investors have recently made changes to their positions in the business. World Investment Advisors grew its position in shares of DiaMedica Therapeutics by 7.7% during the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock worth $294,000 after purchasing an additional 2,650 shares in the last quarter. Invesco Ltd. lifted its holdings in DiaMedica Therapeutics by 29.9% in the 4th quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock worth $148,000 after purchasing an additional 4,293 shares in the last quarter. XTX Topco Ltd bought a new position in DiaMedica Therapeutics in the 4th quarter worth approximately $234,000. Wellington Management Group LLP purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at approximately $825,000. Finally, Quadrature Capital Ltd purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at approximately $188,000. 10.12% of the stock is currently owned by hedge funds and other institutional investors.
DiaMedica Therapeutics Stock Performance
NASDAQ:DMAC opened at $6.77 on Friday. The stock has a 50-day simple moving average of $7.87 and a two-hundred day simple moving average of $7.65. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $10.42. The firm has a market capitalization of $352.58 million, a PE ratio of -9.67 and a beta of 1.09.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. The company had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $13.50 million. Equities analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.
About DiaMedica Therapeutics
DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.
DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.